Corrigendum

Corrigendum to “Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer”

Shahla Bari,1 Jameel Muzaffar,2 Austin Chan,3 Sanjay R. Jain,3 Ahmad M. Haider,4 Marjorie Adams Curry,5 and Christopher J. Hostler6

1Internal Medicine, Morehouse School of Medicine, Atlanta, GA, USA
2Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, USA
3Morehouse School of Medicine, Atlanta, GA, USA
4AGCO Corporation, Atlanta, GA, USA
5Grady Health System, Department of Pharmacy and Drug Information, Atlanta, USA
6Division of Infectious Diseases, Duke University Health System, Durham VA Health Care System, Durham, NC, USA

Correspondence should be addressed to Shahla Bari; shahlabari9@gmail.com

Received 2 July 2019; Accepted 4 July 2019; Published 21 August 2019

Copyright © 2019 Shahla Bari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer” [1], Drs. Jameel Muzaffar, Ahmad M. Haider, and Marjorie Adams Curry were missing from the authors’ list.

Dr. Jameel Muzaffar, MD, was responsible for manuscript guidance and preparation.

Dr. Ahmad M. Haider was responsible for statistical analysis and chart preparation.

Dr. Marjorie Adams Curry was responsible for providing partial list of patients who were treated with PD1 inhibitors.

The corrected authors’ list is shown above, and it has been added in-line to the published article.

References
